Equities

SkinBioTherapeutics PLC

SBTX:LSE

SkinBioTherapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)20.25
  • Today's Change-0.75 / -3.57%
  • Shares traded487.12k
  • 1 Year change8.00%
  • Beta1.8880
Data delayed at least 20 minutes, as of Feb 06 2026 15:31 GMT.
More ▼

Profile data is unavailable for this security.

About the company

SkinBioTherapeutics plc is a United Kingdom-based life science company focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health, and commercialization of these technologies, as well as the manufacture and sales of dermatological products through acquired entities. Its segments include UK, US, EU, and RoW. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis-a chronic inflammatory condition of the skin.

  • Revenue in GBP (TTM)4.64m
  • Net income in GBP-696.25k
  • Incorporated2015
  • Employees41.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Solvonis Therapeutics PLC0.00-2.60m16.34m--16.34m--
Fusion Antibodies PLC1.60m-1.47m19.07m24.0019.07m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m30.68m10.0030.68m10.00
ImmuPharma PLC0.00-3.93m32.73m6.0032.73m6.00
hVIVO PLC51.28m5.28m41.91m301.0041.91m301.00
Skinbiotherapeutics PLC4.64m-696.25k54.37m41.0054.37m41.00
Hemogenyx Pharmaceuticals PLC0.00-7.81m59.93m16.0059.93m16.00
4Basebio PLC1.78m-14.41m87.02m--87.02m--
Bioventix PLC13.12m7.58m90.91m16.0090.91m16.00
Scancell Holdings Plc4.71m-5.51m134.91m60.00134.91m60.00
Data as of Feb 06 2026. Currency figures normalised to SkinBioTherapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

3.99%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 30 Nov 20247.00m2.70%
Premier Fund Managers Ltd.as of 31 Jul 20252.95m1.14%
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025381.81k0.15%
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.